((自动化翻译由路透提供，请见免责声明 ))
12月26日 - ** 券商H.C. Wainwright将药物开发商Rapt Therapeutics 的评级从 "中性 "上调至 "买入
* (link) * RAPT Therapeutics 与中国上海济民康健药业有限公司（Shanghai Jemincare Pharmaceutical Co.
** RAPT 计划开发 RPT904，首先用于治疗食物过敏。
** 券商称，"投资者应该注意到，食物过敏市场是一个巨大且利润丰厚的细分市场，"据估计，美国约有 3300 万人至少患有一种食物过敏症。
** 经纪公司预计，假设 RPT904 于 2031 年在美国上市，到 2037 年，其年销售额将达到 54 亿美元的峰值
** 称RPT904在慢性自发性荨麻疹(CSU) （一种皮肤病）方面的销售峰值可接近5亿美元
** 券商估计 RPT904 用于食物过敏症的获批概率为 40%，用于 CSU 的获批概率为 30
** 截至上次收盘，股价累计下跌 93
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.